ExpreS2ion Biotech Holding AB (DE:5JD0)

FRANKFURT:5JD0

5JD0

ExpreS2ion Biotech Holding AB

RESEARCH TOOLSreports

ExpreS2ion Biotech Holding AB (5JD0) Price & Analysis

2 Followers

5JD0 Stock Chart & Stats

€1.37

-€0.04(-2.01%)

At close: Jan 08 4:00 PM EST

€1.37

-€0.04(-2.01%)

Day’s Range― - ―

52-Week Range€0.29 - €2.47

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€2.26M

Enterprise Value-€26.77M

Total Cash (Recent Filing)€47.55M

Total Debt (Recent Filing)€2.21M

Price to Earnings (P/E)―

Beta1.76

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.22

Shares Outstanding3,530,233

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.27

Price to Sales (P/S)12.37

P/FCF Ratio-1.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-2.49

Revenue Forecast (FY)€923.72K

Bulls Say, Bears Say

Bulls Say

Proprietary ExpreS2 PlatformExpreS2's proprietary insect-cell expression technology is a durable competitive asset: it enables production of complex antigens and VLP components that are hard to replicate, supports repeatable service contracts, and makes the company a sought partner for vaccine and protein developers over the medium term.

Low Financial LeverageVery low debt provides structural financial flexibility for a small biotech: it reduces refinancing/default risk, preserves headroom for R&D or partnership financing, and gives management optionality to pursue development milestones or partnerships without urgent solvency pressure.

Demonstrated Ability To Reduce Cash Burn (2022–24)The company has shown it can materially cut cash burn, indicating management can control operating spending when needed. That operational discipline, if sustained, extends runway and makes external financing needs more manageable across 2–6 months.

Bears Say

Persistent Operating LossesSustained operating and net losses mean the business consumes capital rather than generating it. Over the medium term this forces dependence on external funding, constrains strategic investments, and increases risk that programs or service growth cannot be financed internally.

Eroding Balance-sheet BaseMaterial contraction of assets and equity reflects cumulative losses and weak capital retention. A shrinking balance sheet reduces financial buffers, limits borrowing capacity, and leaves less room to absorb R&D or clinical setbacks without dilutive financings.

Small, Volatile And Declining RevenueVolatile and shrinking top-line undermines prospects for self-sustaining operations: without durable revenue growth, platform services and partnered programs may fail to scale, prolonging losses and making it harder to convert technical strengths into predictable cash generation.

5JD0 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was €0.29 and its highest was €2.47 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is €2.26M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

ExpreS2ion Biotech Holding AB’s upcoming earnings report date is May 28, 2026 which is in 52 days.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Feb 19, 2026. The company reported -€0.22 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.22.

Is ExpreS2ion Biotech Holding AB overvalued?

According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 3,530,233 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -€0.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.853%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in DE:5JD0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.